Diabetes Journey supports healthcare professionals (HCPs) in the treatment of patients with type 2 diabetes.
The product is a decision support service, that offers objective recommendations on the most efficacious medications for the HCP to consider.
The project was developed for a global pharmaceutical company all the way from concept creation to launch in Southeast Asia.
Diabetes is a chronic disease that occurs when the pancreas is no longer able to make insulin, or when the body cannot make good use of the insulin it produces. In 2019 an approximate of 463 million adults (20-79 years) were living with diabetes; by 2045 this number will rise to 700 million1.
Diabetes is often referred to as a global pandemic. The disease is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years2.
Delayed Injection Initiation
Less than 7% of all people with diabetes achieve their desired outcomes3. This is due to a multitude of reasons including, compliance, motivation, education, cost of medication and suboptimal medication regimen. Personalizing the treatment of diabetes is a known challenge and daily struggle of physicians. Guidelines published by ADA and EASD are complex and personalizing the treatment is a challenging exercise. For HCPs with less than 10-15 minutes per patient adhering to the guidance can prove an insurmountable task.
Intensification of the medication regimen is generally too slow. 31% of patients on 2nd line OADs are not in control of their diabetes4. For patients on a Sulfonylurea + Metformin combo it takes up to 5 years to intensify the treatment with other glucose-lowering treatments, even in the presence of elevated HbA1c5.
HCPs have only 10-15 minutes per patient.
Less than 7% of patients achieve the desired treatment outcomes.
Sub-optimal treatment increases costs by a factor of 2 to 4.
Empowering Physicians to Enhance the Treatment of Diabetes
Diabetes Journey is available both as a web and mobile application for iOS and Android. The app has launched in Vietnam and Bangladesh and directly supports the HCP to personalize the treatment of their patients.
The app is the worlds first model-based digitalized diabetes guideline, offering objective recommendations on the best medications for the HCP to consider.